We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
Figure 1.

Figure 1. From: Effect of epigallocatechin gallate supplementation in schizophrenia and bipolar disorder: an 8-week, randomized, double-blind, placebo-controlled study.

Epigallocatechin-3-gallate (EGCG) versus placebo: clinical assessment results. Mean (± SEM) scores by group for all research participants completing 10 weeks of the study are shown. (a) Clinical Global Impressions (CGI). The CGI was administered at baseline (week 0) and at week 10 (after 8 weeks of double-blind, placebo-controlled treatment with EGCG or placebo). (b)–(d) Results from (b) the Positive and Negative Syndrome Scale (PANSS), (c) Hamilton Rating Scale-Anxiety (HAM-A), and (d) Hamilton Rating Scale-Depression (HAM-D). These measures were administered at baseline (week 0), week 6, and week 10.

Jennifer M. Loftis, et al. Ther Adv Psychopharmacol. 2013 February;3(1):21-27.

Supplemental Content

Filter your results:

Search details

See more...

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...
Write to the Help Desk